JAK Inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19

Curr Drug Res Rev. 2022;14(2):85-87. doi: 10.2174/2589977514666220304203816.
No abstract available

Publication types

  • Editorial

MeSH terms

  • COVID-19 Drug Treatment*
  • Cytokine Release Syndrome / drug therapy
  • Cytokines
  • Humans
  • Janus Kinase Inhibitors* / pharmacology
  • Janus Kinase Inhibitors* / therapeutic use
  • SARS-CoV-2

Substances

  • Cytokines
  • Janus Kinase Inhibitors